Vi
Non verificato

Vir Biotechnology, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute
28/10/2026
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
1.00
21/10/2026
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
1.00
14/10/2026
Software
Scienza
Associazioni/Professionisti
Farmaceutica
Information Technology
Oncologia
Tecnica
Comunicazione
Biotecnologia
Salute
Mercato del lavoro
Industria
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
1.00
08/10/2026
Industria
Igiene alimentare
Terza età
Medicina - Varie
Biotecnologia
Salute
Vetrine/Shopping
Farmaceutica
Oncologia
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
1.00
07/10/2026
Mercato del lavoro
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology Appoints David Liu as Chief Medical Officer
1.00
05/10/2026
Fiere
Eventi
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
1.00
01/10/2026
Mercato del lavoro
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
1.00
31/08/2026
Web e Social Network
Eventi
Fiere
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
1.00
05/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
1.00
24/07/2026
Mercato del lavoro
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Vir Biotechnology Announces Chief Financial Officer Transition
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0